Antibiotics provide no benefit for patients with idiopathic pulmonary fibrosis, study finds
Doctors have hoped that antibiotics could benefit patients with chronic lung diseases, but a new study has found no benefit for patients with life-threatening idiopathic pulmonary fibrosis in preventing hospitalization or death.
While there were no statistical benefits for patients with the lung-scarring disease, the new research will prevent unnecessary antibiotic use that could contribute to the growing problem of antibiotic resistance. The nationwide clinical trial - believed to be the largest idiopathic pulmonary fibrosis trial ever conducted - also collected biological samples that will advance the understanding and treatment of the mysterious and ultimately fatal illness.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Pulmonary Fibrosis Foundation Urges COVID-19 Vaccination In Letter To Patients
December 28, 2020 GMT
The Pulmonary Fibrosis Foundation s Medical and Scientific Advisory Board is recommending COVID-19 vaccination for individuals with pulmonary fibrosis.
The Pulmonary Fibrosis Foundation s Medical and Scientific Advisory Board is recommending COVID-19 vaccination for individuals with pulmonary fibrosis.
CHICAGO, Dec. 28, 2020 /PRNewswire/ The Pulmonary Fibrosis Foundation (PFF) is encouraging COVID-19 vaccination for individuals with pulmonary fibrosis, a progressive and debilitating lung disease affecting more than 200,000 Americans.
In a letter to the PF community, the PFF Medical & Scientific Advisory Board strongly recommends vaccination, along with the safe practices of physical distancing, hand washing, and face coverings, to help prevent COVID-19 illness.